Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/azilsartan/hydrochlorothiazide

Next Previous
Drug Profile

Amlodipine/azilsartan/hydrochlorothiazide

Alternative Names: Amlodipine/hydrochlorothiazide/azilsartan; Azilsartan/amlodipine/hydrochlorothiazide; Azilsartan/hydrochlorothiazide/amlodipine; Hydrochlorothiazide/amlodipine/azilsartan; Hydrochlorothiazide/azilsartan/amlodipine; TAK-536/AML/HCTZ; TAK-536TCH

Latest Information Update: 04 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class Antihypertensives; Benzimidazoles; Benzothiadiazines; Dihydropyridines; Oxadiazoles; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Essential hypertension

Most Recent Events

  • 04 Jul 2017 Chemical structure information added
  • 10 May 2017 Discontinued - Preregistration for Essential hypertension in Japan (PO) based on the outcomes of market research (Takeda FY2016 Q4 results, May 2017)
  • 01 Jun 2016 Takeda completes a phase III trial in Essential hypertension in Japan (NCT02277691; JapicCTI-142689)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top